Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ...

Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price objective reduced by HC Wainwright from $27.00 to $18.00 in ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Enanta Pharmaceuticals (ENTA) announced Tuesday it would appeal a recent U.S. federal court ruling that favored Pfizer ...

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the ...

H.C. Wainwright lowered the firm’s price target on Enanta (ENTA) to $18 from $27 and keeps a Buy rating on the shares. Zelicapavir successfully ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...

US-based biotechnology company Enanta Pharmaceuticals has reported positive topline outcomes from its randomised Phase II ...

Check the time stamp on this data. Updated AI-Generated Signals for Enanta Pharmaceuticals Inc. (ENTA) available here: ENTA.

Enanta Pharmaceuticals (ENTA) announced that the United States District Court of Massachusetts has issued a ruling on a summary judgment motion ...